Morgan Stanley lifted their target price on shares of Seattle Genetics from $64.00 to $69.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 31st. It has outperformed by 58.98% the S&P500. It was reported on Dec, 1 by Barchart.com. (NASDAQ:SGEN) on Thursday, June 15 with "Hold" rating.
Among 5 analysts covering Compugen (NASDAQ:CGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Compugen had 8 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has "Sell" rating by Zacks on Monday, September 21. As per Monday, December 12, the company rating was downgraded by Credit Suisse. Capital International Inc bought 13,930 shares as the company's stock rose 1.68% with the market. The firm earned "Hold" rating on Wednesday, November 8 by Oppenheimer.
Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 11 Hold.
Investors sentiment increased to 1.52 in Q2 2017. For the next fiscal year, analysts anticipate that the business will post earnings of ($1.25) per share, with EPS estimates ranging from ($2.03) to ($0.28). 138 funds opened positions while 500 raised stakes. Envestnet Asset Mgmt invested in 0% or 1,813 shares. First Manhattan Co. now owns 3,150 shares of the biotechnology company's stock worth $162,000 after purchasing an additional 750 shares during the last quarter. South Dakota Inv Council stated it has 34,000 shares. Its down 6.56% from 12.72 million shares, reported previously. BlackRock Investment Management LLC boosted its position in Seattle Genetics by 0.4% in the third quarter. (NASDAQ:CRIS). Sabby holds 0.01% or 48,000 shares. (NASDAQ:SGEN). Vanguard Grp, a Pennsylvania-based fund reported 7.53M shares. Baillie Gifford And holds 1.1% or 15.84 million shares.
Cornercap Investment Counsel Inc increased Abbvie Inc Com (ABBV) stake by 19.73% reported in 2017Q2 SEC filing. Natl Bank Of New York Mellon Corp has 359,352 shares for 0% of their portfolio. Pacad Limited reported 26,800 shares or 0.2% of all its holdings. (NYSE:ABBV). Dreman Value Mngmt L L C has invested 0.83% in AbbVie Inc. The stock decreased 0.10% or $0.05 during the last trading session, reaching $50.28. About 4.68M shares traded or 281.56% up from the average. Seattle Genetics has a 52 week low of $35.93 and a 52 week high of $75.36. It has underperformed by 46.64% the S&P500.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. Seattle Genetics posted earnings per share of ($0.23) in the same quarter last year, which suggests a negative year over year growth rate of 91.3%. More interesting news about Seattle Genetics, Inc. Grandfield & Dodd LLC now owns 10,001 shares of the biotechnology company's stock valued at $517,000 after acquiring an additional 495 shares in the last quarter. State Street reported 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN) has "Hold" rating given on Tuesday, June 6 by Cowen & Co. Seattle Genetics had 56 analyst reports since July 31, 2015 according to SRatingsIntel. (NASDAQ:SGEN) rating on Monday, October 10. On Friday, September 15 the stock rating was maintained by Needham with "Buy". Quantbot Technologies LP boosted its position in Seattle Genetics by 116.5% in the third quarter. Carl Domino holds 5,200 shares. SunTrust maintained Seattle Genetics, Inc. ValuEngine upgraded Seattle Genetics from a "sell" rating to a "hold" rating in a research note on Friday, September 1st. The stock now has a consensus rating of "Hold" and an average price target of $63.53. (NASDAQ:SGEN) for 398,529 shares. Cowen & Co maintained the stock with "Hold" rating in Tuesday, June 6 report.
Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.20, from 1.5 in 2017Q1. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Seattle Genetics in a research note on Friday, October 27th. Oregon Public Employees Retirement Fund raised its position in shares of Seattle Genetics by 1.1% during the 2nd quarter. The biotechnology company reported ($0.19) EPS for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.23. Prelude Cap Management Ltd Liability Company stated it has 0.02% in Seattle Genetics, Inc. Sterling Cap Mngmt Lc has invested 0% of its portfolio in Seattle Genetics, Inc. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since December 3, 2016 and is uptrending. (NASDAQ:SGEN) for 39,030 shares. Caxton Assoc Ltd Partnership invested in 5,200 shares. Captrust Financial Advsr accumulated 200 shares or 0% of the stock. (NASDAQ:SGEN) for 15,000 shares. 5,035 are owned by Capstone Asset Mgmt. Arrowstreet Capital Limited Partnership increased its stake in Seattle Genetics by 6.6% in the second quarter. 1,900 were accumulated by Livforsakringsbolaget Skandia Omsesidigt.
Since June 14, 2017, it had 0 insider purchases, and 2 sales for $8.79 million activity.
In related news, CFO Todd E. Simpson sold 39,385 shares of the business's stock in a transaction that occurred on Wednesday, November 1st. In other Seattle Genetics news, insider Vaughn B. Himes sold 10,000 shares of the firm's stock in a transaction dated Friday, March 31st.
Chatham Lodging Trust's (NYSE:CLDT) Sentiment is 1.63
Cisco Systems Inc. has $160 highest and $16 lowest target. $35.68's average target is -5.11% below currents $37.6 stock price. The stock of Chatham Lodging Trust (NYSE:CLDT) earned "Equal-Weight" rating by Barclays Capital on Wednesday, November 1.